Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer
Phase 1/2 dose escalation study to assess the safety and tolerability of ARV-110 in men with mCRPC who have progressed on prior approved systemic therapies for their castrate resistant disease (one of which must be enzalutamide or abiraterone).
Prostate Cancer Metastatic
DRUG: ARV-110
Part A: Incidence of Dose Limiting Toxicities of ARV-110, First Cycle Dose limiting toxicities characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study drug, 28 Days|Part A: Number of Patients with Adverse Events as a measure of safety and tolerability of ARV-110, Adverse events as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study drug., 28 Days|Part A: Incidence of laboratory abnormalities as a measure of safety and tolerability of ARV-110, Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing., 28 Days|Part B: Measurement of PSA response rate per PCWG3 accessing anti-tumor activity of ARV-110, PSA response rate per PCWG3., 12 Weeks|Part B: Measurement of overall RECIST response rate accessing the anti-tumor activity of ARV-110, Overall RECIST response rate in patients with measurable disease at baseline., 12 Weeks|Part B: To evaluate the clinical anti-tumor activity of ARV-110 in patients with mCRPC, To evaluate the clinical anti-tumor activity (PSA response rate per PCWG3, Overall RECIST RR, rPFS, and PFS) of ARV-110 in patients with mCRPC in different subgroups of patients with mCRPC with predefined tumor genomic and molecular profiles or based on prior therapy., 12 Weeks
Part A: Anti-tumor activity based on the overall PSA response in the entire study population and in the subsets of patient based on the AR mutational status of their tumor., The anti-tumor activity of ARV-110 will be assessed by evaluating the overall PSA response per PCWG3., 12 Weeks|Part A: Anti-tumor activity based on the overall RECIST response in the entire study population and in the subsets of patient based on the AR mutational status of their tumor., The anti-tumor activity of ARV-110 will be assessed by evaluating the overall RECIST response rate., 12 Weeks|Part A: Anti-tumor activity based on the progression free survival in the entire study population and in the subsets of patient based on the AR mutational status of their tumor., The anti-tumor activity of ARV-110 will be assessed by evaluating the time to event progression free survival., 12 Weeks|Part A: Anti-tumor activity based on the duration of response in the entire study population and in the subsets of patient based on the AR mutational status of their tumor., The anti-tumor activity of ARV-110 will be assessed by evaluating the duration of response., 12 Weeks|Part A: Anti-tumor activity based on the time to progression in the entire study population and in the subsets of patient based on the AR mutational status of their tumor., The anti-tumor activity of ARV-110 will be assessed by evaluating the time to progression., 12 Weeks|Part A: Anti-tumor activity based on the overall survival in the entire study population and in the subsets of patient based on the AR mutational status of their tumor., The anti-tumor activity of ARV-110 will be assessed by evaluating the overall survival., 12 Weeks|Part A: Concentration-time curve (AUC) for single and multiple dose of ARV-110, PK parameters will be assessed when applicable after a single dose and after multiple once and twice daily doses. Assessment of pharmacokinetic parameter area under the concentration-time curve (AUC)., 28 Days|Part A: Maximum concentration (Cmax) for single and multiple dose of ARV-110, PK parameters will be assessed when applicable after a single dose and after multiple once and twice daily doses. Assessment of pharmacokinetic parameter maximum concentration (Cmax)., 28 Days|Part A: Minimum concentration (Cmin) for single and multiple dose of ARV-110, PK parameters will be assessed when applicable after a single dose and after multiple once and twice daily doses. Assessment of pharmacokinetic parameter minimum concentration (Cmin)., 28 Days|Part A: Time to maximum concentration (Tmax) for single and multiple dose of ARV-110, PK parameters will be assessed when applicable after a single dose and after multiple once and twice daily doses. Assessment of pharmacokinetic parameter time to maximum concentration (Tmax), 28 Days|Part B: Concentration-time curve (AUC) for single and multiple dose of ARV-110, PK parameters will be assessed when applicable after a single dose and after multiple once and twice daily doses. Assessment of pharmacokinetic parameter area under the concentration-time curve (AUC)., 28 Days|Part B: Maximum concentration (Cmax) for single and multiple dose of ARV-110, PK parameters will be assessed when applicable after a single dose and after multiple once and twice daily doses. Assessment of pharmacokinetic parameter maximum concentration (Cmax)., 28 Days|Part B: Minimum concentration (Cmin) for single and multiple dose of ARV-110, PK parameters will be assessed when applicable after a single dose and after multiple once and twice daily doses. Assessment of pharmacokinetic parameter minimum concentration (Cmin)., 28 Days|Part B: Time to maximum concentration (Tmax) for single and multiple dose of ARV-110, PK parameters will be assessed when applicable after a single dose and after multiple once and twice daily doses. Assessment of pharmacokinetic parameter time to maximum concentration (Tmax), 28 Days|Part B: Duration of response, From the date of first confirmed best overall response of CR or PR to the date of first progression per RECIST 1.1 or PCWG3, or death due to any cause without evidence of radiographic progression, whichever occurs first., 12 Weeks|Part B: Overall survival, Time interval from the date of first ARV-110 dose to the date of death due to any cause., 12 Weeks
Phase 1/2 dose escalation study to assess the safety and tolerability of ARV-110 in men with mCRPC who have progressed on prior approved systemic therapies for their castrate resistant disease (one of which must be enzalutamide or abiraterone).